Wishing you all the joys of the season! 
North America Intravenous Immunoglobulin Market Size and Forecasts (2020-2030)
North America Intravenous Immunoglobulin Market Size and Forecasts (2020 – 2030), Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (IgG, IgA, IgM, and Others), Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Idiopathic Thrombocytopenic Purpura, Multifocal Motor Neuropathy, Hypogammaglobulinemia, Guillain-Barre Syndrome, Specific Antibody Deficiency, Inflammatory Myopathies, Myasthenia Gravis, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Country (US, Canada, and Mexico)
$2,100 – $3,500
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
New Product Launches and Approvals Opportunity for Growth of Intravenous Immunoglobulin Market
In recent years, there have been various developments in the intravenous immunoglobulin market in North America. Market players have been launching new products and seeking regulatory approvals for their offerings. In April 2023, Takeda Pharmaceutical Company Limited, an R&D-driven biopharmaceutical leader, received a supplemental Biologics License Application (sBLA) approval from the US Food and Drug Administration (FDA) to expand the use of HYQVIA to treat primary immunodeficiencies (PI) in children belonging to the age group of 2–16 years. Only HYQVIA’s subcutaneous immune globulin (ScIG) infusion allows for monthly administration. In 2022, Health Canada approved HyQvia, a new Immunoglobulin (IG) treatment for Canadians with immune deficiencies. In February 2021, Pfizer Inc. received an sBLA approval for PANZYGA (10% liquid intravenous immunoglobulin preparation) to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
Type-Based Insights
The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030.
Application-Based Insights
Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030.
Distribution Channel -Based Insights
Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030.
End User – Based Insights
Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030.
Patients with autoimmune diseases are treated with intravenous immunoglobulins. Autoimmune diseases are conditions wherein the immune system accidentally attacks its own tissues or cells. Chronic inflammation, and organ and system damage result from this aberrant immune reaction against healthy cells. Fatigue, joint pain, muscle weakness, skin rashes, and neurological disturbances are a few of the typical signs and symptoms of autoimmune diseases. Symptoms of autoimmune diseases such as Guillain-Barré syndrome (GBS), myasthenia gravis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (LE), and immune thrombocytopenia (ITP) can be alleviated with the IVIG therapy. Benefits of this therapy include the rapid relief of symptoms and long-lasting effects, leading to improved quality of life among patients.
According to the Intermountain Healthcare, autoimmune and immune-mediated diseases and conditions affect 23.5–50 million Americans. According to the Centers for Disease Control and Prevention, rheumatoid arthritis (RA) is the most prevalent type of autoimmune arthritis, and 1 in 4 adults in the US has arthritis. As per the Myasthenia Gravis Foundation of America, Inc., the prevalence of myasthenia gravis (MG) is estimated at 14–20 per 100,000 of the US population. In Canada, the incidence of MG is estimated to be 23 per 1 million person-years, with a prevalence of 263 per 1 million people, and the numbers have been stable over the past few decades.
Increase in Use of Immunoglobulins Bolsters North America Intravenous Immunoglobulins Market
Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is rising with the surging use of these antibodies for treating various conditions.
Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the leading companies operating in the intravenous immunoglobulin market.
A few of the major primary and secondary sources referred to while preparing the report on the North America intravenous immunoglobulin market are the Myasthenia Gravis Foundation of America, Journal of Allergy and Clinical Immunology, Genetic and Rare Diseases Information Center, Immune Deficiency Foundation, GBS Foundation, Centers for Disease Control and Prevention
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. The deficiency of immunoglobulin requires the external administration of immunoglobulin and is known as immunoglobulin replacement therapy (IgRT). IgRT can be given intravenously and subcutaneously. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are selected based on the indication and severity. IVIg is manufactured from human plasma. It contains antibodies and is used to treat many immunologic, haematologic, and neurologic illnesses.
Plasma-derived immunoglobulins are used for treating autoimmune and inflammatory disorders, among others. In addition to autoimmune and acute inflammatory conditions, primary immune deficiency disease (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) are the chronic and acute conditions that are treated with immunoglobulins. Immunoglobulins are also increasingly used to manage infectious diseases, dermatological conditions, rheumatological/nephrological conditions, and heart disease. Thus, the demand for intravenous immunoglobulins is on the rise with the surging use of these antibodies for treating various conditions
Table: Common Use and Dosing for Intravenous Immunoglobulins
Disease/Medical Condition FDA Approval Status Goal of Therapy
B-Cell Chronic Lymphocytic Leukemia (CLL) Yes Prevention of bacterial infections due to hypogammaglobinemia
Bone Marrow Transplantation Complications Yes Prevention of infections, pneumonitis, and acute graft-versus-host disease (GVHD) following bone marrow transplantation
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Yes Improvements in patients suffering from neuromuscular disability and impairment, and maintenance therapy to prevent relapse
HIV Infection Yes Reduction of serious bacterial infections in pediatric patients infected with HIV
Idiopathic Thrombocytopenic Purpura (ITP, CITP) Yes Increase platelet count in ITP to prevent or control bleeding
Kawasaki Disease Yes Prevention of coronary artery aneurism associated with Kawasaki disease
Multifocal Motor Neuropathy (MMN) Yes Modulation of immune-inflammatory condition, improvement of muscle strength, and management of disability in adult patients
Primary Immunodeficiency Disease (PIDD) Yes Protection against frequent and/or severe infections (bacterial and viral)
Source: Academy of Managed Care Pharmacy
Leading players in the intravenous immunoglobulin market have multiple projects and many biological products in pipelines based on proprietary technologies. Evolve Biologics plans to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. It completed the Phase III clinical trial for its IVIG candidate in February 2021, and it intends to develop a portfolio of this product candidate. Similarly, Biotest, offering plasma protein products and biotherapeutic drugs, is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation from human plasma to treat immunodeficiencies and autoimmune diseases through intravenous administration. In September 2020, the company completed its Phase III trial investigating the administration of IgG Next Generation for treating patients with PIDs. In May 2020, the US Food and Drug Administration (FDA) approved Octapharma’s Investigational New Drug (IND) application to initiate a Phase 3 trial of Octagam (immune globulin intravenous) to treat patients suffering from COVID-19, with severe disease progression.
Companies are investing in scientific and technical excellence to develop and introduce new IVIG therapies against immunodeficiencies. Thus, a strong pipeline of IVIG candidates would lead to a significant growth trend in the North America intravenous immunoglobulin market in the future.
Takeda Pharmaceutical Co Ltd; Grifols SA; Pfizer Inc.; ADMA Biologics, Inc.; Bio Products Laboratory Ltd; Octapharma AG; Kedrion SpA.; CSL Ltd.; LFB Group; and Prothya Biosolutions B.V are among the key players operating in the global North America intravenous immunoglobulin market.
The report segments the North America intravenous immunoglobulin market as follows:
The North America intravenous immunoglobulin market, by type, is segmented into IgG, IgA, IgM, and others. In 2022, the IgG segment held the largest share and is expected to record the fastest CAGR during 2022–2030. Based on application, the North America intravenous immunoglobulin market is classified into immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, idiopathic thrombocytopenic purpura, multifocal motor neuropathy, hypogammaglobulinemia, Guillain-Barre syndrome, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. In 2022, the immunodeficiency diseases segment held the largest market share, and it is expected to register the highest CAGR during 2022–2030. Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. In 2022, the hospital pharmacy segment held the largest share, and it is expected to record the fastest CAGR during 2022–2030. Based on end user, the North America intravenous immunoglobulin market is classified into hospitals, specialty clinics, and others. In 2022, the hospitals segment held the largest share, and it is expected to register the fastest CAGR during 2022–2030. Based on country, the North America intravenous immunoglobulin market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest market share. The intravenous immunoglobulins market in Canada is expected to grow at the highest CAGR during 2022–2030.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America intravenous immunoglobulin market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook coupled with the factors driving the North America intravenous immunoglobulin market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Intravenous Immunoglobulin Market, by Geography
2.2 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Intravenous Immunoglobulin Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Intravenous Immunoglobulin Market – Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Increase in Use of Immunoglobulins
5.1.2 Rising Immunodeficiency Disease Prevalence
5.2 Market Restraints
5.2.1 High Cost of Therapy
5.3 Market Opportunities
5.3.1 New Product Launches and Approvals
5.4 Future Trends
5.4.1 Strong Pipeline of IVIG Candidates
5.5 Impact Analysis:
6. Intravenous Immunoglobulin Market – North America Market Analysis
6.1 Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 – 2030
7. North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 – by Type
7.1 Overview
7.2 Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.4 IgA
7.4.1 Overview
7.4.2 IgA: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.5 IgM
7.5.1 Overview
7.5.2 IgM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
8.3 Immunodeficiency Diseases
8.3.1 Overview
8.3.2 Immunodeficiency Diseases: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Idiopathic Thrombocytopenic Purpura
8.5.1 Overview
8.5.2 Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Multifocal Motor Neuropathy
8.6.1 Overview
8.6.2 Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Hypogammaglobulinemia
8.7.1 Overview
8.7.2 Hypogammaglobulinemia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Guillain-Barre Syndrome
8.8.1 Overview
8.8.2 Guillain-Barre Syndrome: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.9 Specific Antibody Deficiency
8.9.1 Overview
8.9.2 Specific Antibody Deficiency: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.10 Inflammatory Myopathies
8.10.1 Overview
8.10.2 Inflammatory Myopathies: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.11 Myasthenia Gravis
8.11.1 Overview
8.11.2 Myasthenia Gravis: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9. North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 – by Distribution Channel
9.1 Overview
9.2 Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 – by End User
10.1 Overview
10.2 Intravenous Immunoglobulin Market Revenue Share, by Species, 2022 & 2030 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Intravenous Immunoglobulin Market – Geographical Analysis
11.1 North America Intravenous Immunoglobulin Market, Revenue and Forecast To 2030
11.1.1 Overview
11.1.2 North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.3 North America: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.4 North America: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.5 North America: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.6 North America: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7 North America Intravenous Immunoglobulin Market, by Country
11.1.7.1 US
11.1.7.1.1 Overview
11.1.7.1.2 US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.1.3 US: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.1.4 US: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.1.5 US: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.1.6 US: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.2 Canada
11.1.7.2.1 Overview
11.1.7.2.2 Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.2.3 Canada: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.2.4 Canada: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.2.5 Canada: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.2.6 Canada: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
11.1.7.3 Mexico
11.1.7.3.1 Overview
11.1.7.3.2 Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
11.1.7.3.3 Mexico: Intravenous Immunoglobulin Market, by Type, 2020–2030 (US$ Million)
11.1.7.3.4 Mexico: Intravenous Immunoglobulin Market, by Application, 2020–2030 (US$ Million)
11.1.7.3.5 Mexico: Intravenous Immunoglobulin Market, by Distribution Channel, 2020–2030 (US$ Million)
11.1.7.3.6 Mexico: Intravenous Immunoglobulin Market, by End User, 2020–2030 (US$ Million)
12. North America Intravenous Immunoglobulin Market – Industry Landscape
12.1 Overview
12.2 Growth Strategies in North America Intravenous Immunoglobulin Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Takeda Pharmaceutical Co Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Octapharma AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Kedrion SpA
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CSL Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 LFB Group
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Intravenous Immunoglobulin Market Segmentation
Table 2. North America Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 6. US Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 8. US Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Intravenous Immunoglobulin Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Intravenous Immunoglobulin Market, by Type– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Intravenous Immunoglobulin Market, by Application– Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Intravenous Immunoglobulin Market, by Distribution Channel– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 18. Recent Inorganic Growth Strategies in the North America Intravenous Immunoglobulin Market
Table 19. Recent Organic Growth Strategies in North America Intravenous Immunoglobulin Market
Table 20. Glossary of Terms, North America Intravenous Immunoglobulin Market
LIST OF FIGURES
Figure 1. Intravenous Immunoglobulin Market Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Intravenous Immunoglobulin Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Intravenous Immunoglobulin Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Intravenous Immunoglobulin Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 7. IgG: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. IgA: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. IgM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Intravenous Immunoglobulin Market Revenue Share, by Application, 2022 & 2030 (%)
Figure 12. Immunodeficiency Diseases: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Chronic Inflammatory Demyelinating Polyneuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Idiopathic Thrombocytopenic Purpura: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Multifocal Motor Neuropathy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Hypogammaglobulinemia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Guillain-Barre Syndrome: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Specific Antibody Deficiency: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Inflammatory Myopathies: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Myasthenia Gravis: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Intravenous Immunoglobulin Market Revenue Share, by Route of Administration, 2022 & 2030 (%)
Figure 23. Hospital Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Retail Pharmacy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Intravenous Immunoglobulin Market Revenue Share, Species, 2022 & 2030 (%)
Figure 27. Hospitals: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Specialty Clinics: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Others: Intravenous Immunoglobulin Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. North America: Intravenous Immunoglobulin Market, by Key Country – Revenue (2022) (US$ Million)
Figure 31. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. North America Intravenous Immunoglobulin Market, By Key Countries, 2022 and 2030 (%)
Figure 33. US Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Canada Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Mexico Intravenous Immunoglobulin Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Growth Strategies in North America Intravenous Immunoglobulin Market
The List of Companies – North America Intravenous Immunoglobulin Market
o Takeda Pharmaceutical Co Ltd
o Grifols SA
o Pfizer Inc
o ADMA Biologics, Inc
o Bio Products Laboratory Ltd
o Octapharma AG
o Kedrion SpA
o CSL Ltd
o LFB Group
o Prothya Biosolutions B.V
You must be logged in to post a review.
Reviews
There are no reviews yet.